Last edition
News about "chronic spontaneous urticaria (CSU) "
Novartis Wins Health Canada Approval for RHAPSIDO in CSU
Novartis has received Health Canada approval for RHAPSIDO (remibrutinib), a new oral treatment for adults with Chronic Spontaneous Urticari (CSU).
Chronic Spontaneous Urticaria (CSU) | 29/07/2026 | By News Bureau
Celldex Reports Sustained Angioedema Improvement with Barzolvolimab in CSU
Celldex presented long-term data showing barzolvolimab delivered sustained off-treatment improvement in angioedema among patients with Chronic Spontaneous Urticaria (CSU).Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU.
Chronic Spontaneous Urticaria (CSU) | 16/06/2026 | By News Bureau | 112
Celltrion Gets FDA Nod for 300mg OMLYCLO, the First Interchangeable Xolair Biosimilar
The US FDA has approved 300 mg/2 mL prefilled syringe formulation of OMLYCLO (omalizumab-igec), expanding dosing options for patients with certain allergic diseases and supporting more personalised treatment. OMLYCLO—the first and only biosimilar interchangeable with XOLAIR (omalizumab)—previously received approval for its 75 mg and 150 mg strengths.
Chronic Spontaneous Urticaria (CSU) | 03/12/2025 | By Dineshwori | 215
FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.
Chronic Spontaneous Urticaria (CSU) | 03/10/2025 | By Dineshwori | 450
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy